STAT June 4, 2024
Elaine Chen

Good morning. Today, FDA advisers are convening to discuss Lykos Therapeutics’ MDMA-assisted psychotherapy for people with PTSD. It’s a critical meeting — MDMA could be the first Schedule I psychedelic to be deemed to have a medical use. Our reporters Olivia Goldhill and Meghana Keshavan will be live-blogging the meeting all day — tune in here.

The need-to-know this morning

  • It’s a clinical trial readout kind of morning, starting with Viking Therapeutics and its MASH treatment, called VK2809, with mid-stage results.
  • BridgeBio Pharma reported long-term results from a study of its drug called infigratinib for the treatment of achondroplasia, a form of dwarfism.
  • Annexon Biosciences announced the outcome of a Phase 3 study in Guillain-Barré syndrome.

AZ’s CAR-T...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, FDA, Govt Agencies, Mental Health, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Trends
Related Articles:
STAT+: Trump’s FDA director pick has a history of criticizing the agency. Here are seven examples
Trump names nominees to lead CDC, FDA, and his pick for surgeon general
Patient Dies in Gene Therapy Trial, But FDA Permits Neurogene to Proceed With Low Dose
New FDA Panel Weighs In on Regulating Generative AI in Healthcare
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA

Share This Article